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Background: Elevated lipoprotein(a) [Lp(a)] levels predict cardiovascular events incidence in patients with coronary
artery disease (CAD). Genetic variants in the rs3798220, rs10455872 and rs6415084 single-nucleotide polymorphisms
(SNPs) in the Lp(a) gene (LPA) correlate with elevated Lp(a) levels, but whether these SNPs have prognostic value
for CAD patients is unknown. The present study evaluated the association of LPA SNPs with incidence of
subsequent cardiovascular events in CAD patients after percutaneous coronary intervention (PCI).
Methods: TaqMan SNP genotyping assays were performed to detect the rs6415084, rs3798220 and rs10455872
genotypes in 517 Chinese Han patients with CAD after PCI. We later assessed whether there was an association of
these SNPs with incidence of major adverse cardiovascular events (MACE: cardiac death, nonfatal myocardial
infarction, ischemic stroke and coronary revascularization). Serum lipid profiles were also determined using
biochemical methods.
Results: Only the rs6415084 variant allele was associated with higher Lp(a) levels [41.3 (20.8, 74.6) vs. 18.6 (10.3,
40.9) mg/dl, p < 0.001]. During a 2-year follow-up period, 102 patients suffered MACE, and Cox regression analysis
demonstrated that elevated Lp(a) (≥30 mg/dl) levels correlated with increased MACE (adjusted HR, 1.69; 95% CI
1.13-2.53), but there was no association between LPA genetic variants (rs6415084 and rs3798220) and MACE
incidence (p > 0.05).
Conclusions: Our data did not support a relationship between genetic LPA variants (rs6415084 and rs3798220) and
subsequent cardiovascular events after PCI in Chinese Han CAD patients.
Keywords: Coronary artery disease, Lipoprotein(a), Major adverse cardiovascular events, Percutaneous coronary
intervention, Single-nucleotide polymorphism* Correspondence: gzghelain@163.com; zhongshilong@gmail.com
1Department of Cardiology, Guangdong Cardiovascular Institute, Guangdong
Academy of Medical Sciences, Guangdong General Hospital, 96 Dongchuan
Road, Guangzhou 510007, China
2Medical Research Center, Guangdong Cardiovascular Institute, Guangdong
Academy of Medical Sciences, Guangdong General Hospital, 96 Dongchuan
Road, Guangzhou 510007, China
Full list of author information is available at the end of the article
© 2013 Li et al.; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
Li et al. Lipids in Health and Disease 2013, 12:127 Page 2 of 7
http://www.lipidworld.com/content/12/1/127Introduction
Cardiovascular disease is the leading cause of morbidity
and mortality worldwide. In past decades, multiple car-
diovascular disease risk factors have been identified and
used for risk stratification and outcome evaluations; lipo-
protein (a) (Lp(a)) is one of the most attractive and prom-
ising risk factors.
Lp(a) is a plasma lipoprotein consisting of a cholesterol-
rich low density lipoprotein (LDL) particle with one apoli-
poprotein B100 (apoB100) molecule and an additional
apolipoprotein(a) (apo(a)) protein attached via a disulfide
bond [1]. Previous studies demonstrated that elevated Lp
(a) levels are associated with increasing incidence and
severity of cardiovascular diseases [2-7]. Furthermore, ele-
vated baseline Lp(a) levels predict the subsequent cardio-
vascular event incidence in patients with coronary artery
disease (CAD) after percutaneous coronary intervention
(PCI) [8-10].
Serum Lp(a) levels are largely affected by Lp(a) gene
(LPA) variations, which varies widely across different
races [11-13]. Recently, many single-nucleotide polymor-
phisms (SNPs) have been identified in LPA [11,12,14-16].
Among these polymorphisms, rs3798220 and rs10455872
are two common LPA variants that have been studied in-
tensively. Rs3798220 and rs10455872 are short variations
in the 5’ haplotype block of LPA, which is located at the
6q27 chromosomal region. Both of these variations are
strongly associated with serum Lp(a) levels in Caucasians,
and each rs10455872 (G; 7.0% frequency) and rs3798220
(C; 2.0% frequency) minor allele increased log Lp(a) by
1.18 and 1.27 standard deviation units [17], respectively.
A series of case–control studies demonstrated that
rs10455872 and rs3798220 are significantly associated
with CAD and myocardial infarction risk and are also
associated with atherosclerotic burden, obstructed cor-
onary artery number and an earlier CAD diagnosis
[17-19]. However, whether these two LPA SNPs correl-
ate to subsequent cardiovascular event risk for CAD pa-
tients after PCI is unknown. The present study was
therefore aimed to explore the association between the
two aforementioned SNPs in addition to another LPA
SNP rs6415084, which is also a short variation in the 5’
haplotype block of LPA and correlates with Lp(a) levels
[12], and the incidence of subsequent cardiovascular
events in Chinese Han patients with CAD after PCI.
Methods
Study population
In total, five hundred and seventeen Chinese Han pa-
tients from Guangdong General Hospital were sequen-
tially enrolled during May 2009 and August 2010. All of
the patients were between 18 and 80 years old, unrelated
Han Chinese male and female CAD patients. All of the
patients received PCI before discharge. We excludedpatients for any of the following: contraindication to
aspirin or clopidogrel therapy, pre-existing bleeding dis-
orders, pregnancy, lactating or planning to become preg-
nant, advanced cancer, hemodialysis and unsuccessful
genotyping. This study has been registered in the Chinese
Clinical Trial Registry (registration number: ChiCTR-
OCH-11001198). All of the participants provided written
informed consent for genetic analysis. The Guangdong
general hospital ethics committee approved the study.
Genotyping
Genomic DNA was extracted from 4 ml EDTA-
anticoagulated blood with the PureGene DNA isolation
kit (Gentra Systems, Minnesota, USA) according to the
manufacturer’s recommendations. Rs6415084 rs3798220
and rs10455872 of LPA were determined for each
patient using the TaqMan genotype discrimination assay
(Applied Biosystems, California, USA) following the
manufacturer’s instructions.
Lipid profile determination
Serum lipid profiles including total cholesterol, triglyc-
erides, LDL-cholesterol (LDL-C), high-density lipo-
protein cholesterol (HDL-C), apolipoproteinA (apoA),
apolipoproteinB (apoB) and Lp(a) were determined by
biochemical methods on the second day of each pa-
tients’ admission. Lp(a) was measured in serum samples
using sandwich enzyme-linked immunosorbent assays
(ELISA) [Lp(a) ELISA kit, Yaji Biosystems, Shanghai,
China] and a SYNCHRON LX20 UniCel DxC800 analyzer
(Beckman Coulter Inc., USA); less than 30 mg/dl was
considered within the normal range.
Data collection clinical follow-up
Baseline risk factors, coronary angiographic findings and
medication use were recorded for all of the enrolled pa-
tients. Follow-up information was collected based on in-
patient and outpatient hospital visits as well as telephone
contacts with the patients or their families 6, 12, 18,
24 months after PCI. The clinical end point was the cu-
mulative incidence of major adverse cardiovascular events
(MACE) including cardiac death, nonfatal myocardial in-
farction (MI), ischemic stroke (CT or MR scan confirmed)
and coronary revascularization. Coronary revasculariza-
tion included PCI (including atherectomy, balloon angio-
plasty and stenting) or coronary artery bypass grafting in
the follow-up period. For subjects with multiple events,
only the first event was considered for analysis.
Data analysis
Categorical data are reported as frequencies, and differ-
ences between groups were compared with the χ2 test.
Fisher exact tests were used when the expected cell fre-
quencies were less than 5. Continuous data are reported
Table 1 Genotype and allele frequency distribution of











SNP ID n (%) n (%) n (%)
rs6415084 Genotype
CC 406 (78.5) 367 (78.6) 39 (78.0) 0.250
CT 105 (20.3) 94 (20.1) 11 (22.0)
TT 6 (1.2) 25 (1.3) 0 (0.0)
Allele
C 917 (88.7) 828 (85.2) 89 (89.0) 0.302
T 117 (11.3) 144 (14.8) 11 (11.0)
rs3798220 Genotype
CC 433 (83.8) 393 (84.2) 40 (68.1) 0.449
CG 84 (16.2) 74 (15.8) 10 (21.3)
Allele
C 950 (91.9) 860 (91.1) 74 (84.1) 0.870
G 84 (8.1) 74(8.9) 14 (15.9)
rs10455872 Genotype
AA 515 (99.6) 465 (99.6) 50 (100.0) 1.000




932 (99.8) 100 (100.0) 1.000
G 2 (0.2) 2 (0.2) 0 (0.0)
Abbreviations: CAD coronary artery disease, LPA Lp(a) gene, MACE major
adverse cardiovascular event, SNP single nucleotide polymorphism.
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tile range, quartile1-quartile3) for continuous variables,
and differences between groups were assessed using a t-
test or Mann–Whitney U rank-sum test according to
distribution status. All of the SNPs were assessed for
deviations from Hardy-Weinberg disequilibrium with
the use of a χ2 test. If the minor SNP genotype frequency
was less than 5%, the minor genotype was combined
with the intermediate genotype.
Survival curves were generated using the Kaplan–Meier
method and compared using the Log-rank test; univariate
and multivariate Cox proportional hazard regression was
used to find associations with baseline clinical characteris-
tics and 2-year incidence of MACE. Variables with p
values < 0.10 were entered into the multivariable model,Table 2 Serum Lp(a) levels in patients carrying different LPA
SNP rs6415084
genotype CC CT/TT
Lp(a) (mg/dl) 18.6 41.3
(10.3, 40.9) (20.8, 74.6)
Abbreviations: LPA Lp(a) gene, SNP single nucleotide polymorphism.and variables with p values < 0.10 remained in the model.
Because the rs6415084 minor genotype (TT) frequency
was less than 5% and only two rs3798220 and rs10455872
genotypes were detected in our subjects, a dominant effect
model of Cox regression analysis was used to calculate the
hazard ratio (HR) of separate SNP to the incidence of
MACE and corresponding 95% confidence interval (CI).
The wild-type genotype (W)/W was coded as 0, and the
W/variant (V) and V/V genotypes combined were coded
as 1. The significance level for all of the statistical tests
was P < 0.05. Data analyses were performed using SPSS
version 17.0 (Statistical Product and Service Solutions,
Chicago, Illinois, USA).
Results
LPA SNP genotype and allele frequency distribution
The LPA SNP genotype and allele frequency distribution
are demonstrated in Table 1. Of the three SNPs studied,
both rs6415084 and rs3798220 were prevalent in our co-
hort except rs10455872, for which the variant allele was
present in only two patients (G). The variant rs6415014
(T), rs3798220 (C) and rs10455872 (G) allele frequencies
were 0.113, 0.081 and 0.002, respectively. There were no
significant differences in genotype and allele frequencies
between patients with or without MACE (all p > 0.05).
The effect of LPA SNPs on serum Lp(a) levels in Chinese
Han CAD patients
Patients with the CT/TT genotype had a significantly
higher Lp(a) levels compared with those that have the
rs6415084 CC genotype [41.3 (20.8, 74.6) vs. 18.6 (10.3,
40.9) mg/dl, p < 0.001]. However, there were no signifi-
cant differences in Lp(a) levels between patients with CC
and CG genotype of rs3798220 [23.2 (11.3, 51.9) vs. 18.6
(9.9,46.0) mg/dl, p = 0.411] (Table 2).
Baseline characteristics and their effect on MACE
A total of 517 patients made up our study cohort.
During a 2-year follow-up, 102 patients (19.7%) suffered
at least one incidence of MACE (12.0% coronary revas-
cularization, 3.9% cardiac death, 1.7% non-fatal myo-
cardial infarction, 1.9% ischemic stroke). The baseline
characteristics of patients with or without MACE are
described in Table 3. Multivariable Cox regression ana-
lysis demonstrated that systolic blood pressure (adjusted
HR, 1.02; 95% CI: 1.01-1.03), LVEF (adjusted HR, 0.97;SNP genotypes
p rs3798220 p
CC CG
<0.001 23.2 18.6 0.411
(11.3, 51.9) (9.9,46.0)
Table 3 Baseline characteristics in CAD patients with or
without MACE
Characteristics MACE p
Present, n = 102 Absent, n = 415
Age (yrs) 64.8 ± 12.1 63.1 ± 11.2 0.168
Male (%) 86.3 81.4 0.251
Smokers (%) 30.4 39.3 0.155
Hypertension (%) 66.7.00 56.70 0.105
Diabetes mellitus (%) 30.4 21.9 0.071
History of AMI (%) 35.5 36.8 0.782
History of stroke 4.9 4.6 0.798
Previous PCI 22.5 15.7 0.097
SBP (mmHg) 134.9 ± 23.2 129.7 ± 20.4 0.022
Body mass index (kg/m2) 20.8 ± 7.6 21.4 ± 8.2 0.751
Total cholesterol (mmol/L) 4.39 ± 1.27 4.44 ± 1.22 0.681
Triglycerides (mmol/L) 1.17 (0.87, 1.69) 1.30 (0.98, 1.81) 0.306
LDL-C (mmol/L) 2.71 ± 1.04 2.75 ± 0.99 0.729
HDL-C (mmol/L) 1.08 ± 0.29 1.10 ± 0.30 0.627
Lp(a) (mg/dl) 36.3 (12.8, 56.4) 22.4 (10.5, 45.7) 0.012
hs-CRP (mg/l) 3.34 (1.48, 6.80) 3.33 (1.35, 10.80) 0.200
eGFR (ml/min/1.73 m2) 92.9 ± 34.1 97.5 ± 33.7 0.228
HbAc1 (%) 6.52 ± 0.98 6.41 ± 1.21 0.496
LVEF (%) 56.0 ± 13.7 59.8 ± 10.9 0.003
Coronary type
Stable angina 33.3 22.9 0.029
Unstable angina 28.4 39.5 0.038
AMI 38.2 37.6 0.904
Number of lesion vessels 2.34 ± 0.76 2.15 ± 0.81 0.034
Three-vessel disease 52.0 41.9 0.067
Left main disease 16.7 11.8 0.188
Statins 100 98.1 0.366
β-blockers 74.5 81.4 0.103
ACE inhibitors/ARB 81.4 80.7 0.881
Abbreviations: CAD coronary artery disease, MACE major adverse
cardiovascular event, AMI acute myocardial infarction, SBP systolic blood
pressure, ACE angiotensin converting enzyme, ARB angiotensin receptor
blocker, LDL-c low density lipoprotein cholesterol, HDL-c high density
lipoprotein cholesterol, LVEF left ventricular ejection fraction, hs-CRP high
sensitive reactive protein, eGFR estimated glomerular filtration rate, PCI
percutaneous coronary intervention.
Table 4 Univariate and multivariate analysis for 2-year
MACE incidence
Univariate analysis HR (95% CI) P
Diabetes 1.54 (1.01-2.34) 0.047
Previous PCI 1.56 (0.98-2.49) 0.060
Number of vessels with lesions 1.32 (1,03-1.70) 0.030
β-blocker use 0.65 (0.42-1.02) 0.060
SBP 1.01 (1.01-1.02) 0.026
Lp(a)≥ 30 mg/dL* 1.54 (1.05-2.27) 0.029
LVEF 0.98 (0.96-0.99) <0.001
Multivariate analysis
Diabetes 1.50 (0.98-2.30) 0.061
Previous PCI 1.51 (0.95-2.41) 0.085
β-blocker use 0.62 (0.39-0.97) 0.035
SBP 1.02 (1.01-1.03) <0.001
Lp(a)≥ 30 mg/dL* 1.77 (1.19-2.63) 0.005
LVEF 0.97 (0.96-0.99) <0.001
*Lp(a)<30 mg/dl was used for reference, Multivariate analysis was adjusted for
diabetes, previous PCI, number of lesioned vessels, β-blocker use, SBP, LVEF
and Lp(a) ≥ 30 mg/dL. Abbreviations: LVEF left ventricular ejection fraction,
MACE major adverse cardiovascular event, SBP systolic blood pressure, PCI
percutaneous coronary intervention.
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95% CI: 0.39-0.97) and elevated Lp(a) levels (≥30 mg/dl)
(adjusted HR, 1.77; 95% CI: 1.19-2.63) were independent
MACE predictors (Table 4).
The effects of LPA SNPs on MACE incidence
Figure 1 presents the Kaplan–Meier survival curves for
the separate SNPs according to their genotypes. There
were no significant differences in time to MACE
according to the genotypes of separate SNPs (all p >
0.05). Cox regression analysis demonstrated that there
were no significant associations between the LPA geneticvariants (rs6415084 and rs3798220) and time to MACE;
the adjusted HR (95% CI) for rs6415084 and rs3798220
were 0.91 (0.55-1.50) and 1.51 (0.92-2.45), respectively
(Table 5).
Discussion
In our study, we genotyped three LPA SNPs and evalu-
ated the association of these SNPs with Lp(a) levels in
Chinese Han CAD patients. We found that only the
rs6415084 variant correlated to Lp(a) levels; we further
explored the association of the two SNPs that were most
prevalent in our cohort (rs6415084 and rs3798220) and
found no association between these SNPs and subse-
quent cardiovascular event incidence after PCI.
Serum Lp(a) levels are, to a large extent, genetically
determined by LPA variations in many populations
[11,12], and genetic LPA variations have been linked dir-
ectly with CVD risk [5,7]. Notably, certain genetic LPA
variants, such as SNPs rs3798220 and rs10455872, are
strongly associated with both increased Lp(a) levels and
CAD risk in Caucasians [17]. However, because of race
differences, the genotype frequencies may vary across dif-
ferent races [11,12,17]. As an example, the rs10455872
variant is prevalent and significantly associated with ele-
vated Lp(a) levels in Caucasians; however, the variant al-
lele frequency (G allele) of this SNP is very low (<1%) in
Chinese people without CAD [12]. We also found a simi-
lar low frequency of this SNP variant allele in our study
cohort with CAD. The rs3798220 minor allele (G allele)
frequency in the Chinese is relatively higher than the
Caucasians (8.1% vs. 1.4%); however, this variation was not
Figure 1 Kaplan-Meier survival curves of LPA SNPs and time to MACE. Panels A, B demonstrate the Kaplan-Meier MACE survival curves
according to rs6415084 and rs3798220 genotypes, respectively. MACE: major adverse cardiovascular events, including cardiac death, nonfatal
myocardial infarction, ischemic stroke and coronary revascularization.
Table 5 Association between Lp(a) genetic variants and
2-year MACE incidence
SNP ID Genotype Frequency MACE HRadj p
n, (%) (95% CI)
rs6415084 CC 406 (78.5) 82 (20.2) 0.90 0.681
CT/ TT 111 (21.5) 20 (18.0) (0.55-1.48)
rs3798220 CC 433 (83.8) 80 (18.5) 1.50 0.092
CG 84 (16.2) 22 (26.2) (0.94-2.41)
HRadj: use a multivariate Cox regression model that has been adjusted for
age, diabetes, hypertension, previous PCI, 3-vessel disease, β-blocker use, total
cholesterol, eGFR, LVEF and coronary artery disease type.
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patients. The reason for the lack of association is uncer-
tain and may be partially explained by allele frequency dif-
ferences or apo(a) size heterogeneity, which is the result of
a genetically determined functional copy number variation
within LPA [20], but these hypotheses must be tested in
further studies. In our study, rs6415084 was the only SNP
that was associated with serum Lp(a) levels, which is con-
sistent with a population-based study [12]. Interestingly,
the rs6415084 variant allele frequency in our study was
0.11, which was similar to that of Chinese people with-
out CAD in a SHARE cohort [12,21]. These data suggest
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pathogenesis, but this hypothesis must be assessed in
further studies.
Accumulating evidence has suggested that Lp(a) plays
an important role in promoting cardiovascular disease.
Elevated Lp(a) levels (≥30 mg/dl) reportedly predict sub-
sequent cardiovascular event incidence in Caucasians
with stable coronary disease, especially in patients with
suboptimal LDL-C control (≥70 mg/dl) [10]. Recently,
Zhou et al. [9] determined that Lp(a) levels at admission
are an independent risk factor for subsequent adverse
cardiovascular events in Chinese patients with acute cor-
onary syndrome, especially in patients younger than
60 years old. In our study, we found a similar association
between elevated Lp(a) levels (≥30 mg/dl) and subse-
quent adverse cardiovascular events in CAD patients
after PCI; elevated Lp(a) levels were associated with
1.77-fold greater likelihood of MACE. Our data and
others support the notion that Lp(a) may be used for
risk stratification and outcome evaluations.
Although LPA SNP variants correlated with elevated
Lp(a) levels [12,17], which were associated with high
MACE incidence for CAD patients after PCI, there was
no direct association between LPA SNP variants and
MACE incidence. LPA variants rs3798220 and rs10455872
have been strongly associated with both increased Lp(a)
levels and increased CAD risk [17]. However, because of
racial differences, the rs3798220 and rs10455872 variant
allele frequency in our cohort was different from the fre-
quency in Caucasians. Both of these SNPs had no signifi-
cant effect on serum Lp(a) levels in our cohort; therefore,
one would not expect that they would have an effect on
MACE incidence. Although the rs6415084 variant was
strongly associated with higher Lp(a) levels, we did not
discover a direct association between rs6415084 polymor-
phisms and MACE incidence during a 2-year follow-up.
Our result is similar to a study by Nicholls et al., who de-
termined that LPA SNPs rs2048327, rs3127599, rs7767084
and rs10755578 as well as haplotypes correlated to plasma
Lp(a) levels, and Lp(a) levels ≥30 mg/dl were associated
with MACE in stable CAD patients during a 3-year
follow-up; however, this group did not observe any associ-
ation of the LPA SNPs/haplotypes with increased pro-
spective MACE risk.
CAD is a multi-factorial disease, and multiple genetic
variations combined with environmental factors may re-
sult in phenotypic variability; therefore, factors that cause
cardiovascular events in CAD are complicated. Compared
to risk factors such as Lp(a) levels, disease severity, thera-
peutic reactions and therapeutic adherence are more
effective measures for predicting CAD prognosis. In our
study, elevated Lp(a) levels were an independent MACE
predictor; however, elevated Lp(a) levels were a result of
each Lp(a) genetic variant but not any specific SNP. Ofthe SNPs, rs3798220 explained approximately 8% of total
(both genetic and individual-specific) variation in Lp(a)
levels, and rs10455872 explained approximately 25% of
the variation. Together these two SNPs explained 36% of
the variation in Lp(a) levels in Caucasians [17]; however,
in our study, rs6415084 explained only approximately 4%
of total variation in Lp(a) levels (data not shown). Thus, it
was not surprising that there was no significant associ-
ation between the rs6415084 variant and MACE inci-
dence. To date, our data and others do not support use of
Lp(a) genetic variants for CAD risk stratification and out-
come evaluations. However, because only three LPA SNPs
were genotyped, and a relatively small patient sample size
was involved in present study, further studies with more
LPA SNPs and larger patient sample sizes will be required
to confirm this conclusion.
Conclusions
Taken together with previous and present studies, our
data did not support a relationship between genetic LPA
variants rs6415084, rs3798220 and subsequent cardio-
vascular event incidence after PCI in Chinese Han CAD
patients; however, other studies will be required to con-
firm these findings.
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